Assessing HER2 Status Across Tumor Types

Now Viewing

EP: 1.Assessing HER2 Status Across Tumor Types

EP: 2.ADCs Targeting HER2+ Breast Cancer

EP: 3.ADCs Targeting HER2+ Gynecologic Cancers

EP: 4.Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

EP: 5.ADCs Targeting GI Cancers

EP: 6.ADCs Targeting HER2+ Lung Cancer

EP: 7.Impact of ADCs on Brain Metastases

EP: 8.ADCs Targeting HER2+ GU Cancers

EP: 9.Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

EP: 10.The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

EP: 11.Managing ILD and Pneumonitis Risk From ADCs

EP: 12.Managing Toxicities in Short- and Long-Term Treatment with ADCs

EP: 13.Managing Hematologic AEs Associated with ADC Treatments

EP: 14.Management of Emetogenicity of Antibody-Drug Conjugates

EP: 15.ADC Sequencing

EP: 16.Emerging ADCs in Development

EP: 17.Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

EP: 18.The Future for HER2-Directed ADCs

EP: 19.Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

• How do HER2 mutations differ from HER2 overexpression and gene amplification in terms of their impact on cancer?
  • How can this differ among cancer types?
• What are the incidences of HER2 overexpression across solid tumors? HER2 mutations?
• What is your current practice for testing for HER2? What testing methodologies are used? How do they differ and what can you learn from each?
  • What is the difference between HER2 amplification and IHC score? What are best practices to ensure patients with HER2 amplification aren’t missed?
  • Does this vary among solid tumors?
  • How have levels of HER2 expression changed? What percent of patients typically have HER2-low expression?
• Is what is known about HER2 expression/mutations from research in breast and other cancer types applicable to other solid tumor types? Are there unique aspects to consider?
• How might current understanding of HER2 expression and HER2 mutations in other solid tumors contribute to the development of future targeted therapies or personalized treatment approaches?